You are here: Industry Insights > Enerzair Breezhaler

News List

High-dose Enerzair Breezhaler further cuts asthma exacerbations pharmatimes
September 08, 2020
A high dose of Novartis' Enerzair Breezhaler (indacaterol acetate, glycopyrronium bromide and mometasone furoate/IND/GLY/MF) significantly reduced asthma exacerbations compared to a medium dose, shows a new analysis.
Novartis receives EC approval for Enerzair Breezhaler americanpharmaceuticalreview
July 16, 2020
Novartis announced the European Commission (EC) has approved Enerzair® Breezhaler® (QVM149; indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]) as a maintenance treatment of asthma in adult patients not adequately ...
Novartis banks EC approval for Enerzair Breezhaler pharmatimes
July 08, 2020
The European Commission (EC) has approved Novartis' Enerzair Breezhaler (indacaterol acetate, glycopyrronium bromide and mometasone furoate) for uncontrolled asthma.
Vectura Earns $5M Novartis Milestone for Enerzair Breezhaler contractpharma
July 08, 2020
Enerzair Breezhaler uses Vectura’s formulation IP, and is a first-in-class fixed-dose combination maintenance treatment for uncontrolled asthma.
EMA recommends eight drugs for approval from April meeting europeanpharmaceuticalreview
May 08, 2020
The EMA’s human medicines committee has adopted a positive opinion for eight medicines, recommending their marketing authorisation.
Novartis receives CHMP positive opinion for Enerzair Breezhaler pharmaceutical-business-review
May 06, 2020
Novartis announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion.
CHMP puts eight new medicines forward for approval pharmatimes
May 06, 2020
The European Medicines Agency's human medicines committee (CHMP) has put forward eight medicines for approval at its April meeting.